Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
By J. Neoptolemos, D. Stocken, Claudio Bassi, P. Ghaneh, David Cunningham, David Goldstein, R. Padbury, Malcolm J. Moore, Steven Gallinger, Christophe Mariette and 17 more. Journal of the American Medical Association (JAMA), 2010
1,134 citations recorded by the source corpus.
Subfields: Biotechnology, Oncology, Surgery
View Paper: https://www.semanticscholar.org/paper/362a0c00e42eb1d643d1d58cd6e3135193d07441
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Surgery
Citations in the corpus
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, methodology): “The ESPAC-3 trial compared the administration of adjuvant chemotherapy with six cycles of either fluorouracil and folinic acid or gemcitabine [30].”
- 30 years of NF-κB: a blossoming of relevance to human pathobiology (2017, positive): “The key oncogenic role of NF-κB is evident in other types of lymphoma, especially Burkitt’s lymphoma, caused in part by EBV which induces NF-κB through its LMP-1 function (Neoptolemos et al., 2010).”
- A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer (2016, methodology): “The median OS of 24·2 months that we found in patients with LAPC (stage III) treated with FOLFIRINOX is the same as the median OS for patients with resected pancreatic cancer (stage I or II) followed by adjuvant gemcitabine in the ESPAC-3 trial.(34) This raises the question whether neoadjuvant FOLFI”
- Recent progress in pancreatic cancer (2013, methodology): “Similarly, the European Study Group for Pancreatic Cancer (ESPAC)-3 phase 3 trial randomized 1088 patients to bolus 5-FU daily with folinic acid for 5 days every 4 weeks or gemcitabine weekly for 3 weeks every 4 weeks for 6 cycles total.(145) The OS was 23.”
- Pancreatic ductal adenocarcinoma: Long-term survival does not equal cure (2012, neutral): “014 Negative 72 (76) 42 (68) 30 (91) Positive 23 (24) 20 (32) 3 (9) Perineural invasion NS No 23 (25) 14 (22) 9 (29) Yes 56 (60) 42 (68) 14 (45) Unknown 16 (15) 6 (10) 9 (26) Perivascular invasion NS No 32 (34) 18 (29) 13 (42) Yes 22 (23) 17 (28) 4 (13) Unknown 41 (43) 27 (43) 15 (45) Grade NS Moder”
- Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. (2012, background): “Additional data on adjuvant chemotherapy (FU or gemcitabine) in distal bile duct cancers is awaited from the planned subset analysis of the ESPAC-3 (European Study Group for Pancreatic Cancer-3) trial.(34) Given the retrospective nature of these studies, and given the lack”